Investigational drug · Phase 3
Olorofim
Also called: F901318
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
23
Any phase or sponsor naming "Olorofim"
First trial start
2022
Apr 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olorofim", any sponsor or status.
- Phase 118
Conditions studied
As listed on its trial records.
- Coccidioidomycosis
- Disseminated Fungal Infection
- Coccidioides Infection
- Coccidioides Immitis Infection
- Coccidioides Posadasii Infection
- Coccidioidomycosis Infection
- San Joaquin Valley Fever
- Valley Fever
- Invasive Aspergillosis
Approved drugs for the same conditions: Fungal infections · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Olorofim" as an intervention, largest first.
- Olorofim Aspergillus Infection StudyPivotal-lookingCompleted
F2G LtdIndustry
NCT05101187 · 225 participants · Start Apr 29, 2022 · Primary completion Nov 18, 2025
Drug: Olorofim; AmBisome® · For: Invasive Aspergillosis
Sites: Birmingham, Alabama; Duarte, California; Sacramento, California · 143 sites in all
F2G Biotech GmbHIndustry
NCT03583164 · 203 participants · Start Jun 6, 2018 · Primary completion Feb 10, 2023
Drug: Olorofim · For: Invasive Fungal Infections
Sites: Bakersfield, California; Sacramento, California; San Diego, California · 82 sites in all
F2G LtdIndustry
NCT02342574 · 72 participants · Start Feb 2015 · Primary completion Sep 2016
Drug: F901318; Placebo · For: Invasive Aspergillosis
Sites: London, United Kingdom
F2G LtdIndustry
NCT07712484 · 50 participants (planned) · Start Dec 2026 · Primary completion Jun 2028
Drug: Olorofim; Placebo · For: Coccidioidomycosis; Disseminated Fungal Infection; Coccidioides Infection and 5 more
F2G LtdIndustry
NCT02394483 · 46 participants · Start Oct 2015 · Primary completion Sep 2016
Drug: F901318 safety; F901318 tolerability and 1 more · For: Invasive Aspergillosis
Sites: Merthyr Tydfil, United Kingdom
F2G LtdIndustry
NCT03340597 · 45 participants · Start Dec 12, 2017 · Primary completion Apr 13, 2018
Drug: F901318 · For: Invasive Aspergillosis
Sites: Leeds, United Kingdom
F2G LtdIndustry
NCT02737371 · 40 participants · Start May 2016 · Primary completion May 22, 2017
Drug: F901318 Dose level A oral; Placebo dose level A oral and 4 more · For: Invasive Aspergillosis
Sites: Merthyr Tydfil, United Kingdom
F2G LtdIndustry
NCT02142153 · 40 participants · Start Aug 2014 · Primary completion Oct 2014
Drug: F901318; Placebo · For: Invasive Aspergillosis
Sites: Merthyr Tydfil, United Kingdom
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic ImpairmentCompleted
F2G Biotech GmbHIndustry
NCT04752540 · 32 participants · Start Jul 2, 2021 · Primary completion Oct 24, 2021
Drug: Olorofim · For: Hepatic Impairment
Sites: Tustin, California; Orlando, Florida
- Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon OlorofimCompleted
F2G LtdIndustry
NCT04171739 · 24 participants · Start Nov 18, 2019 · Primary completion Feb 11, 2020
Drug: Itraconazole oral solution; Rifampicin Oral Capsule and 1 more · For: Healthy
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Novel antifungal agents for treating endemic mycoses: hope on the horizon?
Bahr NC, Pasqualotto AC, Thompson GR · Curr Opin Infect Dis 2026
- Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives.
Al-Zoubi RM, Farhan A, Hanbali B, et al. · Eur J Med Chem 2026
- Correction: Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis.
· Ann Intern Med 2026
- First report of proven Fusarium brachygibbosum sinusitis in a paediatric patient with acute myeloblastic leukaemia.
Maldonado-Barrueco A, Del Castillo YM, Baquero-Artigao F, et al. · Eur J Clin Microbiol Infect Dis 2026
- Olorofim for Invasive Fungal Diseases in Patients with Limited or No Treatment Options: A Systematic Review.
Bratosin F, Hogea E, Bogdan IG, et al. · Pathogens 2026
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.
Finkina EI, Shevchenko OV, Gerasimova AA, et al. · Int J Mol Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.